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Abstract 
 
Introduction: This paper reports work undertaken to design two new condition-
specific questionnaires for use in hypothyroidism: the Underactive Thyroid-
Dependent Quality of Life Questionnaire (ThyDQoL) and the Underactive Thyroid 
Treatment Satisfaction Questionnaire (ThyTSQ).  
Methods: Semi-structured interviews exploring quality of life (QoL) and experiences 
of treatment were conducted with 30 women and 8 men with hypothyroidism, (mean 
age 51.9, range 29 – 79 years), 37/38 treated with thyroxine, recruited from hospital 
clinics and primary care. 
Results: Despite thyroxine treatment, most interviewees reported negative impact of 
hypothyroidism on QoL, particularly on energy, physical capabilities, motivation, 
physical appearance and weight. The newly designed ThyDQoL has 18 domains 
covering these and other aspects of life affected by hypothyroidism. It is an 
individualised measure of patients’ perceived impact of hypothyroidism on their QoL, 
which takes into account the importance of personally applicable life domains to the 
patient. A 7-item measure of satisfaction with current treatment was designed 
(ThyTSQ-Present) but interviews also indicated the need for a separate 4-item 
section measuring satisfaction with past treatment around the time of diagnosis 
(ThyTSQ-Past).     
Conclusions: The ThyDQoL and ThyTSQ questionnaires have good face validity 
and content validity for adults with hypothyroidism. They are now ready for use in 
clinical research and psychometric evaluation. 
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Introduction 
 
Hypothyroidism is a life-long chronic disease with multiple aversive symptoms, both 
physiological and psychological, that can have a considerable negative impact on 
quality of life (QoL).  Although there has been much interest in clinical aspects of 
hypothyroidism and its treatment over the past twenty years, psychosocial aspects 
have received less attention. Sonino and Fava have pointed out the need for 
multidimensional assessments of the effects of treatment in thyroid disorders, 
including psychosocial aspects (1). However, there is no published self-completion 
measure of QoL in hypothyroidism.  A literature search found two measures, neither 
of which fulfils the requirements for a condition-specific measure of QoL: the 
Canadian disease-specific Chronic Thyroid questionnaire, comprising questions 
relating to symptoms of hypothyroidism (2), is for completion by health professionals 
during interviews with patients; the QOL-Thyroid Scale evaluates the impact of 
thyroid hormone withdrawal on aspects of QoL of thyroid cancer patients undergoing 
scanning procedures (3), and is not suitable for the great majority of people with 
hypothyroidism. 
 
The simple tablet treatment regimen for hypothyroidism is unlikely to be a major 
cause of dissatisfaction to patients compared with, for example, injecting growth 
hormone to treat growth hormone deficiency. However, some patients with 
hypothyroidism may not be satisfied with thyroxine treatment because they do not 
feel as well as they did before the onset of the thyroid disorder. Many complain of 
persistent symptoms on thyroxine (4).  Patients on thyroxine replacement can have 
significant impairment in psychological well-being compared to controls of similar age 
and sex even though their TSH levels are within the normal laboratory reference 
range (5). Such patients are likely to be dissatisfied with their current treatment. 
There is some evidence of poor adherence to treatment by patients, perhaps 
signifying some dissatisfaction with treatment. Ladenson quoted unpublished data 
from one American clinical laboratory that indicated the possibility that patients do not 
fully adhere to two thirds of thyroxine prescriptions dispensed (6). Toft and Beckett 
reported that “some patients achieve a sense of wellbeing only if free T4 is slightly 
elevated and TSH low or undetectable” (7). There is also discussion in the medical 
literature about the benefits of combined treatment with thyroxine and 
triiodothyronine (8-10). A sensitive measure of treatment satisfaction is needed for 
clinical trials of any new treatments or treatment combinations in the future. No such 
measures of treatment satisfaction are known to exist at present. 
 
This study aimed to design two new condition-specific questionnaires based on the 
views and experiences of people with hypothyroidism: the Underactive Thyroid-
Dependent Quality of Life Questionnaire (ThyDQoL) and the Underactive Thyroid 
Treatment Satisfaction Questionnaire (ThyTSQ). 
  
Methods 
Materials 
ThyDQoL questionnaire  
The first draft of the ThyDQoL for use in early interviews was informed by a review of 
the literature on hypothyroidism and discussions with clinicians. Design of the 
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ThyDQoL was based on the Audit of Diabetes-Dependent Quality of Life (ADDQoL) 
(11, 12), which in turn was influenced by the generic interview method known as the 
SEIQoL (Schedule for the Evaluation of Individual Quality of Life) (13).  Adaptations 
of the ADDQoL for people with renal disease (RDQoL) (14), macular disease 
(MacDQoL) (15), diabetic retinopathy (RetDQoL) (16) and growth hormone 
deficiency (HDQoL) (17) were also considered when designing the ThyDQoL, and 
relevant items adapted for inclusion. All these questionnaires define QoL as “how 
good or bad you feel your life to be”, on the basis that QoL is  “what the patient says 
it is” (18).   
 
The first section of the ThyDQoL has two items providing an overview of the 
respondent’s QoL.  Question I (QI - present QoL) asks people to rate their present 
QoL on a 7-point scale from excellent to extremely bad (scored +3 to -3). Question II 
(QII - impact on QoL) asks people to rate what their QoL would be if they did not 
have underactive thyroid, on a 5-point scale from very much better to worse, (scored 
–3 to +1) providing a global measure of perceived impact of underactive thyroid on 
QoL. The first draft ThyDQoL then had 40 life domain items that covered 
relationships, work and leisure, physical aspects including symptoms, cognitive 
aspects including memory, psychological aspects including depression, and 
managing everyday activities. Many of these items were derived from the ADDQoL 
and versions for other disorders (11-17). Domains are introduced by a hypothetical 
statement with 5 response options: e.g. If I did not have underactive thyroid, my 
working life would be... very much better, much better, a little better, the same, worse 
(the impact rating: scored from -3 to +1).  Respondents then rate how important that 
domain is to their QoL on a 4-point Likert scale from very important to not at all 
important (the importance rating: scored from 3 to 0) (Fig. 1). A weighted domain 
impact score is obtained by multiplying the domain’s impact rating by the 
corresponding importance rating. Weighted domain scores range from -9 to +3 
(maximum negative to maximum positive impact of hypothyroidism on the domain). 
Like the ADDQoL, the ThyDQoL is individualised. It takes into account the relevance 
for the individual of each aspect of life covered in the questionnaire, by giving 
respondents the opportunity to indicate whether a particular domain, e.g. work or sex 
life, is not applicable. In a “free comments” section at the end of the questionnaire, 
patients may describe any other ways in which underactive thyroid, and any 
treatment affect their QoL, allowing for the addition of further domains to the 
questionnaire in the future, as part of its continuing development.  
 
[Fig. 1 here] 
 
ThyTSQ questionnaire  
The first draft of the ThyTSQ was prepared after a review of the literature and 
discussions with clinicians. Its design was based on the widely used Diabetes 
Treatment Satisfaction Questionnaire (DTSQ) (19-21) and related questionnaires for 
people with renal disease (RTSQ) (22), Human Immunodeficiency Virus (HIVTSQ) 
(23), and diabetic retinopathy (RetTSQ) (24).  Instructions ask patients to consider 
their experience of treatment for underactive thyroid over the previous few weeks. 
The first draft of the ThyTSQ comprised 10 questions including items concerning 
satisfaction with current treatment, convenience, and understanding of treatment, six 
of which were derived from the DTSQ questionnaire for people with diabetes.  
Patients respond to each item by circling a number on a scale from 6 to 0, indicating 
their degree of satisfaction with that aspect of treatment e.g. from very satisfied to 
very dissatisfied, as in the following example: 
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How satisfied are you with the current treatment for your underactive thyroid? 
very satisfied        6      5         4   3        2        1        0         very dissatisfied 
 
Patient recruitment criteria 
Patients were recruited at three UK centres: Queen Elizabeth Hospital, Gateshead, 
Royal Surrey County Hospital, Guildford, and St Thomas’ Hospital, London, with 
some patients also being identified and recruited at primary care clinics local to the 
Gateshead and London hospitals. Recruitment took place by telephone or in person 
during clinics. The patients were to be representative of the age range and typical 
female: male ratio found in hypothyroidism (approximately 6:1), and of a wide socio-
demographic and ethnic mix, noting that there is higher prevalence of thyroid disease 
in white compared with black people (25). The age range was 18+ years (no upper 
limit). There was to be a broad spectrum of hypothyroidism, ranging from subclinical 
to overt, and including those with post-partum hypothyroidism, or those rendered 
hypothyroid after surgery or radioiodine therapy. The proportion of people with 
subclinical hypothyroidism was limited to a maximum of 10% of the total. The great 
majority of patients would be treated with thyroxine. Exclusion criteria were: 
pregnancy, current or previous thyroid cancer, and non-English-speakers. Patients 
with other chronic conditions such as diabetes or heart disease were not excluded, 
nor were patients with central hypothyroidism, even though the latter might have 
particular difficulty differentiating the symptoms of hypothyroidism from those of other 
pituitary-hypothalamic hormone deficiencies.  
 
Interviews 
Semi-structured interviews were conducted with 38 patients, by psychologists 
experienced in questionnaire design. Each interview lasted approximately 75 minutes 
and was tape-recorded. An iterative approach (16) was used to determine item 
selection for the new questionnaires. Twenty-five of the 38 interviews started with 
open questions about the effects of hypothyroidism on QoL, and experiences of 
treatment. These 25 patients were asked: “If you woke up tomorrow to find that you 
no longer had underactive thyroid, and you were producing normal amounts of 
thyroid hormone, how would that affect your quality of life?” Life domains and aspects 
of treatment mentioned spontaneously by patients and before they were presented 
with draft questionnaires were noted down. Interviewees then completed and 
commented on the draft questionnaires, and possible changes to the questionnaires 
were discussed and new or modified items piloted with subsequent patients. To 
check that questionnaires could be completed easily, without the priming effects of 
previous open questions, 13 of the later interviews were reversed (i.e. the nearly 
finalised draft questionnaires were presented first before any open questions about 
QoL and treatment satisfaction were asked). These 13 patients were not asked the 
above question imagining life without underactive thyroid.  Few “spontaneous” 
mentions were therefore possible in reversed interviews, although some patients 
started to talk freely as soon as the interview started, and any spontaneous mentions 
were noted and included in summaries of spontaneous mentions. Interview data 
were analysed for content. 
 
The following research ethics committees (REC) gave approval for the interview 
study: Gateshead Local REC, South West Surrey Local REC, and Lewisham REC. 
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Results  
Patient recruitment  
Gateshead recruited 18 patients, and one additional volunteer was interviewed (a 
sibling who accompanied her sister to interview but who did not complete the 
questionnaires); Guildford recruited 9 patients and London 10 patients. All but one of 
the 38 interviewees were being treated with thyroxine. All participants were 
diagnosed by primary care practitioners or hospital clinicians after a minimum of two 
thyroid function tests at least three months apart. Table 1 provides details of patient 
characteristics, and shows that patients with a broad spectrum of hypothyroidism 
were recruited.  
[Table 1 here] 
 
(1) ThyDQoL design  
Twenty-six of 34 interviewees did not understand the term “hypothyroidism”.  An 
additional five patients were confused by the distinction between hypo- and hyper-
thyroidism.  On the other hand, the term “underactive thyroid” was used 
spontaneously by 21 patients, and understood by 15 more patients. One patient did 
not understand the term, and one patient was unsure of difference between under- 
and over-active thyroid.  As the term underactive thyroid was understood by the great 
majority of patients, it was used to refer to the hypothyroid condition throughout both 
the ThyDQoL and ThyTSQ questionnaires, after the first few interviews had been 
conducted. The instructions on the finalised questionnaire make it clear to patients 
that they should consider their QoL from the point of view of the treated condition, if 
applicable, as follows:  
The following questions are about how underactive thyroid has affected 
different aspects of your life in recent weeks.  If you are currently being 
treated for underactive thyroid, please consider the effects of the treated 
condition. 
The 25 patients, (those not participating in a reversed interview), who were asked 
how their QoL would be affected if they no longer had underactive thyroid, mentioned 
18 areas of life specifically at this point. The key areas of life affected were: energy, 
weight, physical appearance, bodily discomfort (e.g. cold intolerance, aches and 
pains), and physical capabilities, (see spontaneous mentions in Table 2). 
 
Responses to the two overview items (QI and QII) showed that present QoL was 
between good and excellent for the great majority (81%), and from bad to extremely 
bad for only two patients (6%). Despite this, 62% perceived the overall impact of 
hypothyroidism on QoL as negative, i.e. that their QoL would be better if they did not 
have underactive thyroid.  However, 38% reported that the disorder had no impact on 
their QoL. The selection of 18 domains was arrived at through the iterative interview 
process, taking particular account of the life domains that received spontaneous 
mentions, patients’ marked responses, and comments whilst completing the 
ThyDQoL.  Nine of the 18 domains have “not applicable” response options (Table 2). 
Hypothyroidism was perceived as having a negative impact on these 18 domains by 
30% to 78% of patients, and the domains were important to most people. Table 2 
shows the numbers reporting negative impact (score -3, -2, -1), no impact (0), or 
positive impact (+1), the wide range of responses selected indicating that the 
questionnaire is likely to be responsive to different subgroups of patients with the 
disorder. The most severely impacted domains were: energy, physically do, 
motivation, physical appearance and weight. However, for all 18 domains there were 
some patients who perceived hypothyroidism as having no impact on the domain, 
particularly for domains social life, future, and getting out and about.  In the majority 
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of domains there were no reports of any positive impact of hypothyroidism, as 
expected, but there was one woman who reported the positive impact of having the 
condition diagnosed and successfully treated, after some years of experiencing 
tiredness and other symptoms. Another patient reported a positive impact in that she 
had become more understanding of people with health problems or disabilities.  
Although some domains received few spontaneous mentions, (sex life, relationship, 
future), they were included in the final version of the ThyDQoL as they received 
reports of negative impact on QoL when patients were completing the 
questionnaires, and were usually important when applicable. Item means are shown 
in Table 3 for the 18 patients in the later interviews, (by which stage mostly finer 
adjustments to items were being made, but underlying concepts remained the same). 
These show the greatest negative weighted impact of hypothyroidism was perceived 
to be for bodily discomfort (-4.6 ± 3.95), energy (-4.17 ± 3.09) and motivation (-3.57 ± 
3.03).  
[Tables 2 and 3 here] 
 
Twelve of the final 18 domains on the ThyDQoL were derived from or are similar to 
domains on the ADDQoL (for diabetes). Additional domains not found on the 
ADDQoL were derived from other questionnaires: two from the HDQoL (for growth 
hormone deficiency) and two from the MacDQoL (for macular degeneration).  Weight 
and depression are important further domains, (not used in previous DQOL 
measures), because excessive weight gain and depression following onset of 
hypothyroidism were frequently mentioned as being particularly distressing.  Of the 
40 domains in the first draft ThyDQoL, 18 items were dropped over the course of 
interviews, for the reason that they were, for the great majority of patients, not 
applicable, or not important, and/or not negatively impacted by hypothyroidism, 
and/or there were no spontaneous mentions of the domain before the questionnaire 
item was presented. Items dropped were: feelings about fertility, physical stamina, 
bodily pain, local or long distance journeys, self-confidence, way people in general 
react to me, financial situation, depend on others, depend on medication, sleep, lose 
things, tolerance of stress, handle my personal affairs, shopping, do things for others, 
living conditions, spiritual/ religious life, and people fuss or worry about me. In 
addition four items relating to specific symptoms of hypothyroidism (problems with 
memory, concentration, voice/ speech, and appetite) were also dropped from the 
earlier drafts of the ThyDQoL because the majority of patients reported they were not 
applicable. They have been included, together with other more common symptoms 
mentioned by the patients, in a new short, 15-item Underactive Thyroid Symptom 
Checklist, suitable for self-completion, the development of which will be reported 
elsewhere.  
 
(2) ThyTSQ design 
One aim of the study was to design a measure of patients’ satisfaction with their 
current treatment for hypothyroidism.  However, half the patients in the first sets of 
interviews (10/20) spontaneously reported negative experiences of treatment around 
the time of diagnosis. These negative experiences related to delays in diagnosis, 
and/ or in prescribing thyroxine treatment, and/ or lack of information provided about 
the condition or the treatment. Even though patients’ experience of current treatment 
might be positive, in some cases these past negative experiences interfered with 
completion of questions about current treatment, because patients wanted to express 
their dissatisfaction with earlier treatment/ mistreatment. A separate section was 
therefore drawn up, after half the interviews had been conducted, with questions 
covering satisfaction with past treatment, the ThyTSQ-Past. It is an extension of the 
main questionnaire, which was re-named the ThyTSQ-Present. 
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Following the iterative process, the final version of the ThyTSQ-Present has seven 
items including questions about satisfaction with current treatment, control of 
symptoms of underactive thyroid, convenience, and patient understanding of 
treatment (Table 4). Three items were dropped from the early draft ThyTSQ-Present 
concerning side effects, flexibility and safety of treatment, as these were not 
perceived to be relevant issues by the patients interviewed.  Least satisfaction was 
found for patients’ understanding of their condition (mean 4.58) and for how well the 
treatment was working (mean 4.97), but there were high means (>5.0) for the other 
five items on satisfaction with present treatment.  
 
The ThyTSQ-Past has four items concerning satisfaction with the way doctors dealt 
with the patient or the thyroid condition around the time of diagnosis, and satisfaction 
with information provided about the condition and its treatment.  Sixteen patients 
spontaneously mentioned some dissatisfaction with past treatment before they saw 
the draft ThyTSQ. When draft questions about past treatment were being tested in 
later interviews, 8/18 patients expressed some degree of dissatisfaction with aspects 
of early treatment. Least satisfaction with past treatment was reported for information 
provided by doctors about the condition and about the treatment (both means less 
than 4.0) (Table 4). The wide range of responses selected for the majority of items in 
both treatment satisfaction measures is indicative of the likely responsiveness of 
these measures to different treatments. 
[Table 4 here] 
 
Discussion 
 
This paper has reported the design of two new questionnaires for use with adults with 
hypothyroidism. The ThyDQoL is an individualised patient-centred measure of the 
impact of hypothyroidism on QoL and the ThyTSQ measures satisfaction with 
treatment for this disorder. The ThyDQoL has two overview items to assess current 
QoL and overall impact of hypothyroidism on QoL, and 18 items covering specific 
domains of life that may be impacted by hypothyroidism, domains that were 
important to the great majority of interviewees. The ThyTSQ was divided into two 
separate and independent sections: the 7-item ThyTSQ-Present, which measures 
satisfaction with current treatment for hypothyroidism, and the 4-item ThyTSQ-Past 
measuring past satisfaction with treatment around the time of diagnosis. Our 
experience was that use of the ThyTSQ-Past allowed interviewees to express their, 
often strongly held, views about past treatment and enabled them to focus on current 
treatment when completing the ThyTSQ-Present.  If the ThyTSQ-Past were not used 
it is likely that ThyTSQ-Present scores would be distorted by dissatisfaction with 
earlier treatment.  It appears that perceived misdiagnosis and mistreatment is a 
common experience for people with hypothyroidism.  Interviews were conducted with 
38 people with a range of diagnoses of hypothyroidism and socio-demographic 
characteristics.  As the interviews progressed and patient’s comments on items and 
wording were incorporated into instructions and items, the questionnaires were found 
to be both acceptable to patients (one indication of good face validity), and easily 
understood. No new domains appeared in the later interviews, and thus it can also be 
concluded that the questionnaires have good content validity. Over the course of the 
iterative interview process, many draft items were dropped from the early versions of 
the questionnaires, and new items inserted, or different forms of wording used. This 
has shown the importance of developing condition-specific questionnaires rather than 
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using generic measures, or making superficial modifications to questionnaires 
designed for other conditions.  
 
There is considerable support for the domains selected for inclusion in the ThyDQoL. 
All but two of the final 18 domains were spontaneously mentioned by patients who 
were asked what effect there would be on their QoL if they did not have underactive 
thyroid. The exceptions were holidays and depression, but these were often 
mentioned in other parts of the interviews. Despite treatment with thyroxine, 
hypothyroidism was found to have a negative impact on QoL, particularly for the 
domains of bodily discomfort, energy, motivation, physically do, weight and physical 
appearance.  This confirms the reports of continuing symptoms and effects of 
hypothyroidism on QoL that appear in newsletters produced by thyroid patient 
organisations (e.g. British Thyroid Foundation) and also recent discussion in the 
medical literature (4). In the interviews, patients expressed some dissatisfaction with 
the efficacy of thyroxine treatment in controlling symptoms, and in wider aspects of 
treatment such as their understanding of their hypothyroid condition, and particularly 
dissatisfaction with insufficient or misleading information provided about the 
treatment and the condition around the time of diagnosis. If such dissatisfaction were 
confirmed in a larger study, this would point to the need for improvements in relation 
to effective education about the condition and its treatment.  
 
A problem for a measure of QoL in hypothyroidism is that patients may have treated 
comorbidities such as pernicious anaemia or diabetes, which often have diffuse 
symptoms that are indistinguishable from those caused by hypothyroidism. The 
advantage of the ThyDQoL, however, is that each item specifically mentions  
“underactive thyroid”, encouraging the respondent to focus on this condition rather 
than any others that they might have. There is evidence that the related condition-
specific questionnaire, the ADDQoL for diabetes, is more sensitive to the effects of 
diabetes in those with comorbidities than generic measures of health status (26), and 
we would expect the ThyDQoL to have similar properties. Furthermore the ThyDQoL 
is not designed to distinguish between people who are, for example, depressed for 
reasons unrelated to their hypothyroidism and those who are depressed owing to 
inadequate thyroxine replacement.  However it will distinguish between people who, 
having indicated that they feel depressed, believe that their depression is due to 
hypothyroidism and those that think that they have depression for other reasons (and 
who will indicate that underactive thyroid has had no impact on their feelings of 
depression).  
 
It would be too early to venture at what score someone could be said to have severe 
impairment of QoL related to hypothyroidism based on the results of these 38 
interviews. The ThyDQoL measures patients’ perceptions of the impact of 
hypothyroidism on 18 domains of life. If a patient scores a weighted impact value of 
-9 for a particular domain, then hypothyroidism is perceived by that individual as 
having the maximum negative impact on that domain (score -3), and the domain is 
very important to that individual (score +3). We can also determine the relative 
impact of the disorder on different domains of QoL: for example, the interview study 
found a greater negative impact on bodily discomfort (mean -4.6) than on social life 
(mean -1.35).  The overall total score for the ThyDQoL will provide the average 
weighted impact on QoL, for individual or group comparison with scores of other 
individuals or groups. In diabetes, for example, the Average Weighted Impact score 
was -1.96 for Type I patients in one large study of a representative sample of two 
clinic populations, with this score being described as indicating a “profoundly 
negative” impact of diabetes on QoL (27).  In that study the mean domain weighted 
impact scores ranged from -3.6 to -0.9. 
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The two new measures are designed for use with individuals as part of routine 
clinical care and to evaluate QoL and treatment satisfaction in clinical trials 
comparing treatment regimens for hypothyroidism. Psychometric validation will 
shortly be undertaken to determine the factor structure, internal consistency 
reliability, and method of scoring the questionnaires. This procedure is necessary to 
determine the validity of calculating a total score for each questionnaire, as is the 
case with the related Audit for Diabetes-Dependent Quality of Life (ADDQoL), or 
whether any subscales exist as with the related Diabetes Treatment Satisfaction 
Questionnaire (DTSQ).  In the meantime, each item may be considered separately in 
assessing QoL and treatment satisfaction amongst people with hypothyroidism.  
 
Conclusion  
 
The ThyDQoL is a new individualised patient-centred measure of the impact of 
hypothyroidism on QoL and the ThyTSQ is a measure of satisfaction with treatment 
for this disorder. The questionnaires have good face validity and content validity for 
adults with hypothyroidism. They now require further evaluation in clinical research, 
which will include assessment of the psychometric properties of the instruments. 
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Tables 
 
Table 1: Centre recruitment details and patient characteristics: Total N = 
38 
 
N 
Hospital clinic 26 
Primary care 11 
Source of 
recruitment 
Self-referral 1 
Ratio women: men   30 women: 8 men 
Primary autoimmune 27 (3 of whom had 
subclinical 
hypothyroidism) 
Primary (secondary to 
thyroidectomy or radioiodine) 
9 
Diagnosis of 
hypothyroidism 
Central  2 
Treated with 
thyroxine 
 37 
Osteoarthritis 6 
Asthma 4 
Type 2 Diabetes Mellitus 3 
Pernicious anaemia 3 
Lupus 1 
Rheumatoid arthritis 1  
Other conditions 
Polycystic ovarian syndrome 1 
White Caucasian 35 Ethnicity 
African or Afro-Caribbean 3 
Mean age  
[range]  
51.9 ± 14.8  
[29 – 79] years 
38 
 

Table 2: ThyDQoL. The final items with responses, and frequencies of patient responses 
 
(Maximum N = 37, one patient did not complete the questionnaire)  
 
   Response options 
 
 
No Abbrev- 
iation 
Wording Excellent Very good Good Neither good 
nor bad 
Bad Very bad Extremely 
bad 
Miss- 
ing 
(I) present QoL 
 
In general my present quality of life 
is: 
2 12 15 5 2 0 0 1 
 
 
     Impact ratings     
No Abbrev- 
iation 
Wording Response 
options 
Spont-
aneous 
 
Negative 
impact 
No impact Positive 
impact 
Not at all 
important 
Not 
appli-
cable 
Miss-
ing 
% reports 
negative 
impact 
(II) hypothyroid-
dependent 
QoL 
If I did not have underactive thyroid, my quality 
of life would be: 
better - worse - 23 14 0 - - 0 62% 
  If I did not have underactive thyroid,…..          
1 spare time  I would enjoy the things I do in my spare time: more – less 7 18 17 0 4 - 2 49% 
 
2 working life* 
 
my working life would be: better – worse 4 12 10 0 1 15 0 ‡55% 
3 holidays*  
 
my holidays would be: better – worse 3 21 12 1 3 3 0 ‡62% 
4 family life*  
 
my family life would be: better – worse 4 19 17 1 0 0 0 51% 
5 social life 
 
my social life would be: better – worse 2 16 21 0 3 - 0 43% 
6 relationship* 
 
my closest personal relationship would be: better – worse 1 14 17 0 1 5 1 ‡44% 
7 sex life*  
 
my sex life would be: better – worse 1 11 16 0 2 9 1 ‡39% 
8 physically do  
 
physically I could do: more – less 10 27 9 1 1 - 0 73% 
9 energy  
 
my energy levels would be: higher – lower 24 29 6 2 0 - 0 78% 
10 speed do  
 
the speed I could do things would be: faster – slower 3 21 15 1 1 - 0 57% 
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     Impact ratings     
No Abbrev- 
iation 
Wording Response 
options 
Spont-
aneous 
 
Negative 
impact 
No impact Positive 
impact 
Not at all 
important 
Not 
appli-
cable 
Miss-
ing 
% reports 
negative 
impact 
11 getting out 
and about  
getting out and about (e.g. shopping, short trips)    
would be: 
easier – more 
difficult 
4 18 19 0 3 - 0 49% 
12 household 
tasks 
I could handle my household tasks: better – worse 6 23 14 0 1 - 0 62% 
13 physical 
appearance  
my physical appearance would be: better – worse 14 23 13 1 4 - 0 62% 
14 weight*  
 
my weight would be: better – worse 18 23 9 1 0 3** 1 62% 
15 bodily 
discomfort*  
my experience of bodily discomfort would be: less – greater 14 11 4 0 0 20 2 30% 
16 depressed* 
  
I would feel depressed or low: less – more 7 11 5 0 0 21 0 30% 
17 motivation* 
 
my motivation to do things would be: greater - less 3 26 5 1 0 5 0 70% 
18 future  
 
my feelings about the future (e.g. worries, 
hopes) would be: 
better - worse 1 17 20 0 0 - 0 46% 
 final open 
question 
Are there any other ways in which underactive 
thyroid and any treatment affect your quality of 
life, that have not been covered by the 
questionnaire? (Yes/ No). If yes, please describe 
in the box provided. 
(box in which 
to write 
responses) 
5 patients offered suggestions that were incorporated into subsequent versions 
*indicates items for which an opening question allows the respondent to indicate that the item is not applicable to them, and move on to the next item. 
**from final 18 interviews only, after item was given a “not applicable“ response option. 
‡Percentage reports of negative impact exclude those respondents who indicated the domain was not applicable. 
 
Note that domain wording changed as the questionnaire was developed but the domains remained the same. 
Table 3: ThyDQoL item means and standard deviations from the final 18 interviews.  
No Abbreviation 
 
Mean ± S.D.* N* 
(I) present QoL 
 
1.29 ± 0.99 17
(II) hypothyroid-
dependent QoL 
-1.11 ± 0.96 18
1 spare time 
 
-1.39 ± 2.12 18
2 working life* 
 
-2.56 ± 2.60 9
3 holidays*  
 
-2.40 ± 3.00 15
4 family life*  
 
-3.00 ± 3.43 18
5 social life 
 
-1.35 ± 2.47 17
6 relationship* 
 
-2.25 ± 2.93 12
7 sex life*  
 
-0.58 ± 1.24 12
8 physically do  
 
-3.56 ± 3.37 18
9 energy  
 
-4.17 ± 3.09 18
10 speed do  
 
-3.06 ± 3.65 18
11 getting out and 
about  
-2.83 ± 3.24 18
12 household tasks -2.78 ± 3.04 18
13 physical 
appearance  
-1.94 ± 2.41 17
14 weight*  
 
-3.43 ± 3.16 14
15 bodily discomfort*  
 
-4.60 ± 3.95 10
16 depressed* 
  
-1.60 ± 1.67 5
17 motivation* 
 
-3.57 ± 3.03 14
18 future  
 
-1.89 ± 3.09 18
*data from final 18 interviews only, by which time questionnaire items  were approaching finalisation. 
Table 4: ThyTSQ. The final items with responses, and frequencies of patient responses 
ThyTSQ-Present  
No Abbreviation Wording Response options Spont-
aneous** 
Mean ± SD [range] N* 
1 
 
present 
satisfaction 
How satisfied are you with the current treatment for your underactive thyroid? very satisfied – very dissatisfied 13 5.17 ± 1.05 [3 - 6] 36 
2 how well working How well do you feel the treatment is working? very well – very badly 14 4.97 ± 1.11 [2 – 6] 36 
3 convenient 
 
How convenient have you found your treatment to be recently (e.g. remembering 
to take the medication, getting prescriptions)? 
very convenient – very inconvenient 10 5.08 ± 1.44 [0 – 6] 36 
4 understanding of 
condition 
How satisfied are you with your understanding of your underactive thyroid? very satisfied – very dissatisfied 4 4.58 ± 1.46 [0 – 6] 36 
5 encourage 
 
Would you encourage someone else with underactive thyroid to have your kind  
of treatment? 
Yes, I would definitely encourage 
them – No, I would definitely not 
encourage them 
0 5.56 ± 1.16 [0 – 6] 36 
6 controlling 
symptoms 
How well do you feel that the treatment is controlling symptoms of underactive 
thyroid? 
very well – very badly 4 5.33 ± 0.78 [4 – 6] 12 
7 continue 
 
How satisfied would you be to continue with your present treatment and dose? very satisfied – very dissatisfied 6 5.53 ± 0.84 [3 – 6] 36 
 final open 
question 
Are there any other features of your recent treatment for underactive thyroid, 
causing either satisfaction or dissatisfaction, that have not been covered by the 
questionnaire? (Yes/No). If yes, please describe in the box provided. 
(box in which to write responses) 1 patient offered suggestions that were 
incorporated into subsequent versions 
ThyTSQ-Past 
 
 
  How satisfied were you……     
1 
 
past satisfaction with the way doctors dealt with your underactive thyroid around the time it was 
first diagnosed? 
very satisfied – very dissatisfied 10 4.20 ± 2.35 [0 - 6] 10 
2 information -
condition 
with the information provided by doctors about underactive thyroid?  very satisfied – very dissatisfied 3 3.36 ± 2.06 [0 - 6] 
 
14 
 
3 information -
treatment  
with the information provided by doctors about the treatment for underactive 
thyroid? 
very satisfied – very dissatisfied 5 3.43 ± 2.47 [0 – 6] 14 
4 taken seriously that doctors took you and your underactive thyroid seriously? very satisfied – very dissatisfied 3 4.85 ± 1.77 [1 – 6] 
 
13 
 
 final open 
question 
Are there any other features of your early experiences of treatment for 
underactive thyroid, causing either satisfaction or dissatisfaction, that have not 
been covered by the questionnaire? (Yes/ No). If yes, please describe in the box 
provided.  
(box in which to write responses) 1 patient offered suggestions that were 
incorporated into subsequent version 
*ThyTSQ-Present: N = 36 completed questionnaires (i.e. excludes accompanying sibling and one untreated patient). Lower N (Present and Past versions) indicates those items tested in later 
interviews only, with varying numbers of patients.   
** all centres 
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 Figure Legends 
 
Fig 1: Example of a ThyDQoL domain item with scoring 
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